| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 790.18 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
As doenƧas de origem tromboembĆ³lica continuam a ser um desafio Ć s prĆ”ticas clinicas na atualidade. Apesar das terapias anticoagulantes clĆ”ssicas estarem largamente estudadas e a sua eficĆ”cia ser comprovada, estas possuem muitas limitaƧƵes conhecidas. Por este facto, tĆŖm sido feitos esforƧos para encontrar alternativas viĆ”veis em termos de eficĆ”cia e com perfis de seguranƧa melhorados. Assim, novas classes farmacolĆ³gicas surgiram para tentar responder a estas limitaƧƵes, nomeadamente os anticoagulantes de aĆ§Ć£o direta ou novos anticoagulantes orais. Este trabalho de investigaĆ§Ć£o teve por base uma anĆ”lise da bibliografia disponĆvel, com o intuito de se tentar perceber se estes novos fĆ”rmacos sĆ£o, realmente, alternativas viĆ”veis e vantajosas. Um importante nĆŗmero de estudos mostrou que estes fĆ”rmacos nĆ£o sĆ£o inferiores Ć s terapias clĆ”ssicas em termos de eficĆ”cia e, para alĆ©m disso, apresentaram uma diminuiĆ§Ć£o nas taxas de efeitos secundĆ”rios. No entanto, estes fĆ”rmacos ainda possuem algumas limitaƧƵes e o conhecimento sobre eles ainda nĆ£o estĆ” suficientemente aprofundado, principalmente em subpopulaƧƵes especiais.
Deste modo, Ć© entĆ£o necessĆ”rio o enriquecer do conhecimento cientĆfico sobre esta nova classe, atravĆ©s de mais estudos e ensaios, da farmacovigilĆ¢ncia e da experiĆŖncia adquirida na clĆnica.
Na segunda parte do trabalho Ć© relatada a minha experiĆŖncia pessoal no Ć¢mbito da realizaĆ§Ć£o do estĆ”gio final de curso, explicando as vĆ”rias valĆŖncias e componentes existentes na farmĆ”cia onde decorreu o estĆ”gio, e as atividades por mim realizadas. Foi uma experiĆŖncia muito enriquecedora em termos de aquisiĆ§Ć£o de conhecimento a vĆ”rios nĆveis, tanto cientĆficos como profissionais, deontolĆ³gicos e Ć©ticos.
Thromboembolic diseases continue to be a challenge to clinical practice nowadays. Although the standard anticoagulant therapies are widely studied and its effectiveness is proven, they have many known limitations. For this reason efforts have been made to find viable alternatives in terms of efficiency and improved safety profiles. For that fact, new drug classes have emerged to try to answer these limitations, namely the direct action anticoagulants or novel oral anticoagulants. This research was based on an analysis of available literature, in order to try to understand whether these new drugs really are a viable and advantageous alternative. A significant number of studies have shown that these drugs are not inferior to standard therapies in terms of efficacy and, moreover, showed a decrease in side effect rates. These drugs also have some limitations and knowledge about them is not enough depth, especially in special subpopulations. It will then be necessary to enrich the scientific knowledge of this new class, through more studies and trials, pharmacovigilance and experience in the clinic. In the second part of the work describes my personal experience with the completion of the classās final stage , explaining the various existing valences and components in the pharmacy where the training took place , and the activities carried out by me . It was a very enriching experience in terms of acquisition of knowledge at many levels, both scientific, professional and ethical.
Thromboembolic diseases continue to be a challenge to clinical practice nowadays. Although the standard anticoagulant therapies are widely studied and its effectiveness is proven, they have many known limitations. For this reason efforts have been made to find viable alternatives in terms of efficiency and improved safety profiles. For that fact, new drug classes have emerged to try to answer these limitations, namely the direct action anticoagulants or novel oral anticoagulants. This research was based on an analysis of available literature, in order to try to understand whether these new drugs really are a viable and advantageous alternative. A significant number of studies have shown that these drugs are not inferior to standard therapies in terms of efficacy and, moreover, showed a decrease in side effect rates. These drugs also have some limitations and knowledge about them is not enough depth, especially in special subpopulations. It will then be necessary to enrich the scientific knowledge of this new class, through more studies and trials, pharmacovigilance and experience in the clinic. In the second part of the work describes my personal experience with the completion of the classās final stage , explaining the various existing valences and components in the pharmacy where the training took place , and the activities carried out by me . It was a very enriching experience in terms of acquisition of knowledge at many levels, both scientific, professional and ethical.
Description
Keywords
Antagonistas da Vitamina K Antiagregantes Plaquetares Anticoagulantes de AĆ§Ć£o Direta Anticoagulantes Orais CoagulaĆ§Ć£o DoenƧas TromboembĆ³licas FarmĆ”cia ComunitĆ”ria Novos Anticoagulantes Orais